Navigation Links
Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:8/31/2010

ans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property protection, product development, manufacturing plans and performance, projected changes in the size of our markets, our market share and product sales and other statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships; the market acceptance of our products; our ability to compete with larger, better financed pharmaceutical and biotechnology companies; new approaches to the treatment of our targeted diseases; our expectation of incurring continued losses; our uncertainty of product revenues and profits; our ability to generate future revenues; our ability to raise additional capital to continue our drug development programs; the success of our clinical trials; our ability to develop and commercialize products; our ability to obtain required regulatory approvals; our compliance with all Food and Drug Administration regulations; our ability to obtain; maintain and protect intellectual property rights for our products; the risk of litigation regarding our intellectual property rights; our limited sales and manufacturing capabilities; our dependence on third-party manufacturers and value added resellers; our ability to hire and retain skilled personnel; our volatile stock price; and other risks detailed in Repligen's annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially fr
'/>"/>
SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
2. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
3. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
4. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
5. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
6. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
7. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
8. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
9. Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Pa. , July 1, 2015 ... fully integrated specialty pharmaceutical company focused on developing, ... that Bob Radie , president and chief ... conferences this summer. He will provide an update ... (ketorolac tromethamine) Nasal Spray, approved product ...
(Date:7/1/2015)... July 1, 2015 New exchange plan enrollees ... 2015 compared to the same time a year ago, ... (NASDAQ: ESRX ) Exchange Pulse™ report, released today. ... 2014, the number of new exchange plan enrollees who ... in the first quarter of 2015. However, when evaluating ...
(Date:7/1/2015)... The Haselmeier Group has decided ... Gert Weber has been nominated by the Board ... Executive Officer (CEO) of the Haselmeier Group. This ... Mr. Weber brings more than 20 years of experience ... various executive management positions, the last being Managing Director ...
Breaking Medicine Technology:Egalet to Present at Upcoming Conferences This Summer 2Egalet to Present at Upcoming Conferences This Summer 3Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 2Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 3Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 4Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 5Haselmeier Group Announces the Extension and Reorganization of its Executive Board 2
... 14 ERT (Nasdaq: ERES ) announced today that it will ... 2010 , after the market closes. After the release, the Company will host ... , , ... dial 1-800-860-2442 when calling within the United States or 1-412-858-4600 when ...
... PALO ALTO, Calif. , July 14 ... developed a medical device and procedure to treat vaginal ... accepted for the 2010 International Meetings for the International ... as a joint meeting in 2010, and the International ...
Cached Medicine Technology:ERT to Announce Second Quarter 2010 Results on August 9, 2010 2Viveve-Sponsored Research Accepted for Presentation at Two Prestigious International Conferences 2Viveve-Sponsored Research Accepted for Presentation at Two Prestigious International Conferences 3
(Date:7/1/2015)... ... July 01, 2015 , ... Did you know that infertility in men is ... we at Advanced Fertility Center of Texas (AFCT) would like to talk about some ... is often considered to be a “woman’s issue,” male fertility factors can play a ...
(Date:7/1/2015)... ... July 01, 2015 , ... Convoy of Hope will partner ... Twin Cities on Saturday, August 1, at Spring Lake Park High School. , During ... than $1 million worth of goods and services including free food, health services, family ...
(Date:7/1/2015)... ... July 01, 2015 , ... Scoliosis is a disorder in which the normally straight ... it affects 2 to 3 percent of the population, or an estimated 6 to 9 ... in children between the ages of 10 and 15. Most types of scoliosis are more ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... mesothelioma compensation law has just published a top ten list they hope will ... report. Click here to read it now. , More than ...
(Date:7/1/2015)... ... July 01, 2015 , ... B. E. Smith, the only full-service leadership solutions ... chief nursing officer recruitment for Capital Health in Pennington, N.J. One ... Smith has recently placed more than 1,000 healthcare executives into organizations. , Capital ...
Breaking Medicine News(10 mins):Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... Over Estimated,A UK doctor, and a leading expert warned ... are being overstated, leading to unnecessary panic. // ... Tyne said there was very little evidence suggesting that ... nut allergies had saved lives. ,Writing in ...
... A team from the Medical Research Council suggests that ... triggered by the presence of a hormone in semen.// ... the development of tumors. ,In a report in ... recommend that women having either cancer should ask their ...
... night’s sleep is critical to doing well in school because ... in class and while doing homework.// While this is common ... can be complex; and the rewards for treatment can extend ... be getting a good night’s sleep is that he or ...
... cases in Africa as of last year hover around ... Nations //.The World Health Organization has suggested an intelligent ... ,The WHO has advised that the ... Africa could be used to give an impetus to ...
... emergency unit is said to make patients wait longer than ... ,This news has only added salt to the ... procedures at the ERI following its branding as one of ... ,Recent figures have shown that more than a third of ...
... government today introduced a controversial licensing scheme. According to ... will be permitted to describe the ailments they claim ... aim to bring homeopathic remedies into the area of ... doctors and scientists believe that products with no scientific ...
Cached Medicine News:Health News:Inordinately Long Waiting Times at A&E Infirmary 2Health News:Doctors worried about Homeopathic licensing 2
... Simplex™ P with Tobramycin ... Bone Cement formula, with the ... By maintaining the original formula, ... performance characteristics of Simplex™ P ...
... Flow Analyzer is a fast, clinically proven ... of low and normal-tension glaucoma., ,The Ocular ... clinically proven measurement that improves detection of ... management of glaucoma, and detection of other ...
... Flexible Dosposable Easy Insertion/Removal ... (CSS) provides absolutely reliable support to ... thereby permitting routine phacoemulsification regardless of ... easy (similar to disposable iris retractors), ...
The collagen intracanicular plugs have a smooth proprietary finish that simplifies insertion of the plug. Collagen plugs are ideal for short term, diagnostic and post-surgical occlusion. Plugs are 2m...
Medicine Products: